SELLAS Life Sciences Group, Inc.
US ˙ NasdaqCM ˙ US81642T2096

SecuritySLS / SELLAS Life Sciences Group, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership28,690 shares
Latest Disclosed Value $ 121,359
Prudential Financial Inc ownership in SLS / SELLAS Life Sciences Group, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 28,690 shares of SELLAS Life Sciences Group, Inc. (US:SLS) valued at $121,359 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 7, 2017 disclosing 0 shares of SELLAS Life Sciences Group, Inc.. The current value of the position is $234,971 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F SELLAS LIFE SCIENCES GROUP I COM NEW 81642T209 28,690 28,690 121 0.0001
2017-02-07 2016-12-31 13F GALENA BIOPHARMA COM 363256108 0 -16,680 -100.00 0 -100.00
2016-11-04 2016-09-30 13F GALENA BIOPHARMA COM 363256108 16,680 1,780 11.95 6 -14.29 0.0000
2016-08-09 2016-06-30 13F GALENA BIOPHARMA COM 363256108 14,900 0 0.00 7 -65.00 0.0000
2016-05-09 2016-03-31 13F GALENA BIOPHARMA COM 363256108 14,900 1,100 7.97 20 0.00 0.0000
2016-02-12 2015-12-31 13F GALENA BIOPHARMA COM 363256108 13,800 -100 -0.72 20 -9.09 0.0000
2015-11-10 2015-09-30 13F GALENA BIOPHARMA COM 363256108 13,900 600 4.51 22 -4.35 0.0000
2015-08-06 2015-06-30 13F GALENA BIOPHARMA COM 363256108 13,300 -100 -0.75 23 21.05 0.0000
2015-05-01 2015-03-31 13F GALENA BIOPHARMA COM 363256108 13,400 1,900 16.52 19 11.76 0.0000
2015-02-06 2014-12-31 13F GALENA BIOPHARMA COM 363256108 11,500 600 5.50 17 -22.73 0.0000
2014-11-12 2014-09-30 13F GALENA BIOPHARMA COM 363256108 10,900 -11,700 -51.77 22 -68.12 0.0000
2014-08-13 2014-06-30 13F GALENA BIOPHARMA COM 363256108 22,600 11,300 100.00 69 146.43 0.0001
2014-05-14 2014-03-31 13F GALENA BIOPHARMA COM 363256108 11,300 800 7.62 28 -46.15 0.0001
2014-02-11 2013-12-31 13F GALENA BIOPHARMA COM 363256108 10,500 -500 -4.55 52 108.00 0.0001
2013-11-07 2013-09-30 13F GALENA BIOPHARMA COM 363256108 11,000 11,000 25 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.